razoxane has been researched along with Neutropenia in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baioni, M; Ballardini, M; De Giorgi, U; Ferrari, E; Marangolo, M; Minzi, MR; Rosti, G; Zaniboni, A; Zornetta, L | 1 |
| Al-Khadimi, Z; Chow, WA; Doroshow, JH; Frankel, P; Lawrence, J; Leong, L; Lim, D; Longmate, J; Margolin, K; Morgan, RJ; Raschko, J; Shibata, S; Somlo, G; Synold, TW; Tetef, ML; Twardowski, P; Yen, Y | 1 |
| Hofland, KF; Jensen, PB; Sehested, M; Thougaard, AV | 1 |
| Horton, JJ; Wells, RS | 1 |
| Atherton, DJ; Laurent, MR; Wells, RS; Williams, YF | 1 |
| Catimel, G; Clavel, M; Merrouche, Y | 1 |
| Egorin, MJ; Fry, D; Gradishar, WJ; Liebes, L; Mendoza, S; Sparano, JA; Speyer, J; Sridhara, R | 1 |
| Green, MR; Herndon, JE; Kindler, HL; Kosty, MP; Vogelzang, NJ | 1 |
1 review(s) available for razoxane and Neutropenia
| Article | Year |
|---|---|
Hematopoietic growth factors and chemoprotectants: should we move toward a two-step process for phase I clinical trials in oncology?
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Heart Diseases; Hematopoietic Cell Growth Factors; Humans; Kidney Diseases; Neoplasms; Neutropenia; Razoxane | 1993 |
4 trial(s) available for razoxane and Neutropenia
| Article | Year |
|---|---|
High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides an effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patients with high-risk stage II-IIIA breast cancer.
Topics: Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Count; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Middle Aged; Neutropenia; Paclitaxel; Razoxane; Recombinant Proteins | 2003 |
Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
Topics: Adult; Antibiotics, Antineoplastic; Cardiovascular Agents; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Heart Failure; Humans; Infusions, Intravenous; Levofloxacin; Male; Middle Aged; Neoplasms; Neutropenia; Ofloxacin; Razoxane; Sarcoma; Sepsis; Treatment Outcome | 2004 |
Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Half-Life; Humans; Middle Aged; Neutropenia; Paclitaxel; Razoxane; Remission Induction; Ventricular Function, Left | 1999 |
High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Heart Diseases; Humans; Male; Mesothelioma; Middle Aged; Neutropenia; Razoxane; Thrombocytopenia | 2001 |
3 other study(ies) available for razoxane and Neutropenia
| Article | Year |
|---|---|
Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
Topics: Anemia; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cardiovascular Agents; Cell Culture Techniques; Colony-Forming Units Assay; Daunorubicin; Doxorubicin; Etoposide; Female; Leukopenia; Mice; Neutropenia; Razoxane; Thrombocytopenia | 2005 |
Razoxane: a review of 6 years' therapy in psoriasis.
Topics: Adult; Arthritis; Bone Marrow Diseases; Carcinoma, Squamous Cell; Humans; Leg Ulcer; Neutropenia; Piperazines; Psoriasis; Razoxane; Skin Neoplasms; Time Factors | 1983 |
Razoxane (ICRF 159) in the treatment of psoriasis.
Topics: Adult; Alopecia; Anemia; Arthritis; Bone Marrow Diseases; Female; Humans; Male; Middle Aged; Neutropenia; Piperazines; Psoriasis; Razoxane | 1980 |